PARP Inhibitors: An Innovative Approach to the Treatment of Inflammation and Metabolic Disorders in Sepsis

References

• Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–1310. doi:10.1097/00003246-200107000-00002
   PubMed Web of Science ®Google Scholar
• Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344–353. doi:10.1097/01.CCM.0000194725.48928.3A
   PubMed Web of Science ®Google Scholar
• Reinhart K, Daniels R, Kissoon N, Machado FR, Schachter RD, Finfer S. Recognizing sepsis as a global health priority — a WHO resolution. N Engl J Med. 2017;377(5):414–417. doi:10.1056/NEJMp1707170
   PubMed Web of Science ®Google Scholar
• Kübler A. Definition. In: Kübler A, ed. Sepsis. Wrocław: Edra Urban & Partner; 2017:9–22.
   Google Scholar
• Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1644–1655. doi:10.1378/chest.101.6.1644
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour C, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA - J Am Med Assoc. 2016;315(8):801–810. doi:10.1001/jama.2016.0287
   PubMed Web of Science ®Google Scholar
• De Waele E, Malbrain MLNG, Spapen H. Nutrition in sepsis: a bench-to-bedside review. Nutrients. 2020;12:2. doi:10.3390/nu12020395
   Web of Science ®Google Scholar
• Ingels C, Gunst J, Van den Berghe G. Endocrine and metabolic alterations in sepsis and implications for treatment. Crit Care Clin. 2018;34(1):81–96. doi:10.1016/j.ccc.2017.08.006
   PubMed Web of Science ®Google Scholar
• Fink M. Cytopathic hypoxia in sepsis. Acta Anaesthesiol Scand Suppl. 1997;110:87–95. doi:10.1111/j.1399-6576.1997.tb05514.x
   PubMedGoogle Scholar
• Cohen J, Vincent JL, Adhikari NKJ, et al. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15(5):581–614. doi:10.1016/S1473-3099(15)70112-X
   PubMed Web of Science ®Google Scholar
• Kenig A, Ilan Y. A personalized signature and chronotherapy-based platform for improving the efficacy of sepsis treatment. Front Physiol. 2019;10:1542. doi:10.3389/fphys.2019.01542
   PubMed Web of Science ®Google Scholar
• Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun. 1963;11(1):39–43. doi:10.1016/0006-291X(63)90024-X
   PubMed Web of Science ®Google Scholar
• Bai P. Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance. Mol Cell. 2015;58(6):947–958. doi:10.1016/j.molcel.2015.01.034
   PubMed Web of Science ®Google Scholar
• Pazzaglia S, Pioli C. Multifaceted role of PARP-1 in DNA repair and inflammation: pathological and therapeutic implications in cancer and non-cancer diseases. Cells. 2019;9:1. doi:10.3390/cells9010041
   PubMed Web of Science ®Google Scholar
• Gupte R, Liu Z, Kraus WL. Parps and adp-ribosylation: recent advances linking molecular functions to biological outcomes. Genes Dev. 2017;31(2):101–126. doi:10.1101/gad.291518.116
   PubMed Web of Science ®Google Scholar
• Hottiger MO. Nuclear ADP-ribosylation and its role in chromatin plasticity, cell differentiation, and epigenetics. Annu Rev Biochem. 2015;84:227–263. doi:10.1146/annurev-biochem-060614-034506
   PubMed Web of Science ®Google Scholar
• Ryu KW, Kim DS, Kraus WL. New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases. Chem Rev. 2015;115(6):2453–2481. doi:10.1021/cr5004248
   PubMed Web of Science ®Google Scholar
• Hottiger MO, Hassa PO, Lüscher B, Schüler H, Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci. 2010;35(4):208–219. doi:10.1016/j.tibs.2009.12.003
   PubMed Web of Science ®Google Scholar
• Di Girolamo M, Fabrizio G. The ADP-Ribosyl-Transferases Diphtheria Toxin-Like (ARTDs) family: an overview. Challenges. 2018;9:1. doi:10.3390/challe9010024
   Google Scholar
• Feijs KLH, Verheugd P, Lüscher B. Expanding functions of intracellular resident mono-ADP-ribosylation in cell physiology. FEBS J. 2013;280(15):3519–3529. doi:10.1111/febs.12315
   PubMed Web of Science ®Google Scholar
• Fabrizio G, Scarpa ES, Di Girolamo M. State of the art of protein mono-ADP-ribosylation: biological role and therapeutic potential. Front Biosci. 2015;20:405–430. doi:10.2741/4316
   Web of Science ®Google Scholar
• Kuny CV, Sullivan CS, Spindler KR. Virus–host interactions and the ARTD/PARP family of enzymes. PLoS Pathog. 2016;12(3):e1005453. doi:10.1371/journal.ppat.1005453
   PubMed Web of Science ®Google Scholar
• Bai P, Cantó C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab. 2012;16(3):290–295. doi:10.1016/j.cmet.2012.06.016
   PubMed Web of Science ®Google Scholar
• Xie N, Zhang L, Gao W, et al. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020;5:1. doi:10.1038/s41392-020-00311-7
   PubMed Web of Science ®Google Scholar
• Kameshita I, Matsuda Z, Taniguchi T, Shizuta Y. Poly (ADP-ribose) synthetase. Separation and identification of three proteolytic fragments as the substrate-binding domain, the DNA-binding domain, and the automodification domain. J Biol Chem. 1984;259(8):4770–4776. doi:10.1016/S0021-9258(17)42913-9
   PubMed Web of Science ®Google Scholar
• Tao Z, Gao P, Liu HW. Identification of the ADP-ribosylation sites in the PARP-1 automodification domain: analysis and implications. J Am Chem Soc. 2009;131(40):14258–14260. doi:10.1021/ja906135d
   PubMed Web of Science ®Google Scholar
• Rolli V, O’Farrell M, Ménissier-de Murcia J, de Murcia G. Random mutagenesis of the poly(ADP-ribose) polymerase catalytic domain reveals amino acids involved in polymer branching. Biochemistry. 1997;36(40):12147–12154. doi:10.1021/bi971055p
   PubMed Web of Science ®Google Scholar
• Leung AKL. Poly(ADP-ribose): an organizer of cellular architecture. J Cell Biol. 2014;205(5):613–619. doi:10.1083/jcb.201402114
   PubMed Web of Science ®Google Scholar
• Aberle L, Krüger A, Reber JM, et al. PARP1 catalytic variants reveal branching and chain length-specific functions of poly(ADP-ribose) in cellular physiology and stress response. Nucleic Acids Res. 2020;48(18):10015–10033. doi:10.1093/nar/gkaa590
   PubMed Web of Science ®Google Scholar
• Ruf A, Rolli V, de Murcia G, Schulz GE. The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. J Mol Biol. 1998;278(1):57–65. doi:10.1006/jmbi.1998.1673
   PubMed Web of Science ®Google Scholar
• Kistemaker HAV, Overkleeft HS, van der Marel GA, Filippov DV. Branching of poly(ADP-ribose): synthesis of the core motif. Org Lett. 2015;17(17):4328–4331. doi:10.1021/acs.orglett.5b02143
   PubMed Web of Science ®Google Scholar
• Chen Q, Kassab MA, Dantzer F, Yu X. PARP2 mediates branched poly ADP-ribosylation in response to DNA damage. Nat Commun. 2018;9(1):3233. doi:10.1038/s41467-018-05588-5
   PubMed Web of Science ®Google Scholar
• Pourfarjam Y, Ventura J, Kurinov I, Cho A, Moss J, Kim I-K. Structure of human ADP-ribosyl-acceptor hydrolase 3 bound to ADP-ribose reveals a conformational switch that enables specific substrate recognition. J Biol Chem. 2018;293(32):12350–12359. doi:10.1074/jbc.RA118.003586
   PubMed Web of Science ®Google Scholar
• Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell. 2010;39(1):8–24. doi:10.1016/j.molcel.2010.06.017
   PubMed Web of Science ®Google Scholar
• Alemasova EE, Lavrik OI. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. Nucleic Acids Res. 2019;47(8):3811–3827. doi:10.1093/nar/gkz120
   PubMed Web of Science ®Google Scholar
• Kamaletdinova T, Fanaei-Kahrani Z, Wang Z-Q. The enigmatic function of PARP1: from PARylation activity to PAR readers. Cells. 2019;8(12). doi:10.3390/cells8121625
   PubMed Web of Science ®Google Scholar
• Ke Y, Wang C, Zhang J, et al. The role of PARPs in inflammation-and metabolic-related diseases: molecular mechanisms and beyond. Cells. 2019;8(9). doi:10.3390/cells8091047
   Web of Science ®Google Scholar
• Bai P, Virág L. Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes. FEBS Lett. 2012;586(21):3771–3777. doi:10.1016/j.febslet.2012.09.026
   PubMed Web of Science ®Google Scholar
• Kunze FA, Hottiger MO. Regulating immunity via ADP-ribosylation: therapeutic implications and beyond. Trends Immunol. 2019;40(2):159–173. doi:10.1016/j.it.2018.12.006
   PubMed Web of Science ®Google Scholar
• Andreone TL, O’Connor M, Denenberg A, Hake PW, Zingarelli B. Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts. J Immunol. 2003;170(4):2113–2120. doi:10.4049/jimmunol.170.4.2113
   PubMed Web of Science ®Google Scholar
• Carrillo A, Monreal Y, Ramírez P, et al. Transcription regulation of TNF-α-early response genes by poly(ADP-ribose) polymerase-1 in murine heart endothelial cells. Nucleic Acids Res. 2004;32(2):757–766. doi:10.1093/nar/gkh239
   PubMed Web of Science ®Google Scholar
• Hassa PO, Haenni SS, Buerki C, et al. Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-κB-dependent transcription. J Biol Chem. 2005;280(49):40450–40464. doi:10.1074/jbc.M507553200
   PubMed Web of Science ®Google Scholar
• Liu L, Ke Y, Jiang X, et al. Lipopolysaccharide activates ERK-PARP-1-RelA pathway and promotes nuclear factor-κB transcription in murine macrophages. Hum Immunol. 2012;73(5):439–447. doi:10.1016/j.humimm.2012.02.002
   PubMed Web of Science ®Google Scholar
• Bohio AA, Sattout A, Wang R, et al. c-Abl–mediated tyrosine phosphorylation of PARP1 is crucial for expression of proinflammatory genes. J Immunol. 2019;203(6):1521–1531. doi:10.4049/jimmunol.1801616
   PubMed Web of Science ®Google Scholar
• Fehr AR, Singh SA, Kerr CM, Mukai S, Higashi H, Aikawa M. The impact of PARPs and ADP-ribosylation on inflammation and host-pathogen interactions. Genes Dev. 2020;34(5):341–359. doi:10.1101/gad.334425.119
   PubMed Web of Science ®Google Scholar
• Rosado MM, Bennici E, Novelli F, Pioli C. Beyond DNA repair, the immunological role of PARP-1 and its siblings. Immunology. 2013;139(4):428–437. doi:10.1111/imm.12099
   PubMed Web of Science ®Google Scholar
• Szántó M, Brunyánszki A, Kiss B, et al. Poly(ADP-ribose) polymerase-2: emerging transcriptional roles of a DNA-repair protein. Cell Mol Life Sci. 2012;69(24):4079–4092. doi:10.1007/s00018-012-1003-8
   PubMed Web of Science ®Google Scholar
• Popoff I, Jijon H, Monia B, et al. Antisense oligonucleotides to poly(ADP-ribose) polymerase-2 ameliorate colitis in interleukin-10-deficient mice. J Pharmacol Exp Ther. 2002;303(3):1145–1154. doi:10.1124/jpet.102.039768
   PubMed Web of Science ®Google Scholar
• Iwata H, Goettsch C, Sharma A, et al. PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation. Nat Commun. 2016;7. doi:10.1038/ncomms12849
   Web of Science ®Google Scholar
• Zerfaoui M, Errami Y, Naura AS, et al. Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-κB upon TLR4 stimulation. J Immunol. 2010;185(3):1894–1902. doi:10.4049/jimmunol.1000646
   PubMed Web of Science ®Google Scholar
• Stilmann M, Hinz M, Arslan SÇ, Zimmer A, Schreiber V, Scheidereit C. A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IκB kinase activation. Mol Cell. 2009;36(3):365–378. doi:10.1016/j.molcel.2009.09.032
   PubMed Web of Science ®Google Scholar
• Hassa PO, Covic M, Hasan S, Imhof R, Hottiger MO. The enzymatic and DNA binding activity of PARP-1 are not required for NF-κB coactivator function. J Biol Chem. 2001;276(49):45588–45597. doi:10.1074/jbc.M106528200
   PubMed Web of Science ®Google Scholar
• Hassa PO, Buerki C, Lombardi C, Imhof R, Hottiger MO. Transcriptional coactivation of nuclear factor-κB-dependent gene expression by p300 is regulated by Poly(ADP)-ribose polymerase-1. J Biol Chem. 2003;278(46):45145–45153. doi:10.1074/jbc.M307957200
   PubMed Web of Science ®Google Scholar
• Kiefmann R, Heckel K, Doerger M, et al. Role of PARP on iNOS pathway during endotoxin-induced acute lung injury. Intensive Care Med. 2004;30(7):1421–1431. doi:10.1007/s00134-004-2301-x
   PubMed Web of Science ®Google Scholar
• Olabisi OA, Soto-Nieves N, Nieves E, et al. Regulation of transcription factor NFAT by ADP-ribosylation. Mol Cell Biol. 2008;28(9):2860–2871. doi:10.1128/mcb.01746-07
   PubMed Web of Science ®Google Scholar
• Kraus WL. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol. 2008;20(3):294–302. doi:10.1016/j.ceb.2008.03.006
   PubMed Web of Science ®Google Scholar
• Caiafa P, Guastafierro T, Zampieri M. Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns. FASEB J. 2009;23(3):672–678. doi:10.1096/fj.08-123265
   PubMed Web of Science ®Google Scholar
• Posavec Marjanović M, Crawford K, Ahel I. PARP, transcription and chromatin modeling. Semin Cell Dev Biol. 2017;63:102–113. doi:10.1016/j.semcdb.2016.09.014
   PubMed Web of Science ®Google Scholar
• Yu Z, Kuncewicz T, Dubinsky WP, Kone BC. Nitric oxide-dependent negative feedback of PARP-1 trans-activation of the inducible nitric-oxide synthase gene. J Biol Chem. 2006;281(14):9101–9109. doi:10.1074/jbc.M511049200
   PubMed Web of Science ®Google Scholar
• Anderson P. Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat Rev Immunol. 2010;10(1):24–35. doi:10.1038/nri2685
   PubMed Web of Science ®Google Scholar
• Ke Y, Han Y, Guo X, et al. PARP1 promotes gene expression at the post-transcriptional level by modulating the RNA-binding protein HuR. Nat Commun. 2017;8(1):1–16. doi:10.1038/ncomms14632
   PubMedGoogle Scholar
• Ji Y, Tulin AV. Post-transcriptional regulation by poly(ADP-ribosyl)ation of the RNA-binding proteins. Int J Mol Sci. 2013;14(8):16168–16183. doi:10.3390/ijms140816168
   PubMed Web of Science ®Google Scholar
• Bai P, Cantó C, Oudart H, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 2011;13(4):461–468. doi:10.1016/j.cmet.2011.03.004
   PubMed Web of Science ®Google Scholar
• Cantó C, Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD +? Pharmacol Rev. 2012;64(1):166–187. doi:10.1124/pr.110.003905
   PubMed Web of Science ®Google Scholar
• Brady PN, Goel A, Johnson MA. Poly(ADP-ribose) polymerases in host-pathogen interactions, inflammation, and immunity. Microbiol Mol Biol Rev. 2018;83(1). doi:10.1128/mmbr.00038-18
   PubMed Web of Science ®Google Scholar
• Walko TD, Di Caro V, Piganelli J, Billiar TR, Clark RSB, Aneja RK. Poly(ADP-ribose) polymerase 1-sirtuin 1 functional interplay regulates LPS-mediated high mobility group box 1 secretion. Mol Med. 2014;20(1):612–624. doi:10.2119/molmed.2014.00156
   Google Scholar
• Zhang D, Hu X, Li J, et al. DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD + depletion in experimental atrial fibrillation. Nat Commun. 2019;10:1. doi:10.1038/s41467-019-09014-2
   PubMed Web of Science ®Google Scholar
• Luo X, Lee kraus W. On par with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev. 2012;26(5):417–432. doi:10.1101/gad.183509.111
   PubMed Web of Science ®Google Scholar
• Szabó C. Role of poly(ADP-ribose) polymerase activation in the pathogenesis of inflammation and circulatory shock. In: Bürkle A, ed. Poly(ADP-Ribosyl)ation. Vol. 280. US: Springer; 2006:184–202. doi:10.1007/0-387-36005-0_16
   Google Scholar
• Evgenov O, Liaudet L. Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock. Curr Vasc Pharmacol. 2005;3(3):293–299. doi:10.2174/1570161054368580
   PubMedGoogle Scholar
• Khan AU, Delude RL, Han YY, et al. Liposomal NAD + prevents diminished O2 consumption by immunostimulated Caco-2 cells. Am J Physiol - Lung Cell Mol Physiol. 2002;282(5):L1082–L1091. doi:10.1152/ajplung.00358.2001
   PubMed Web of Science ®Google Scholar
• Fink MP. Bench-to-bedside review: cytopathic hypoxia. Crit Care. 2002;6(6):491–499. doi:10.1186/cc1824
   PubMed Web of Science ®Google Scholar
• Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1 - dependent cell death by apoptosis-inducing factor. Science. 2002;297(5579):259–263. doi:10.1126/science.1072221
   PubMed Web of Science ®Google Scholar
• Du L, Zhang X, Han YY, et al. Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem. 2003;278(20):18426–18433. doi:10.1074/jbc.M301295200
   PubMed Web of Science ®Google Scholar
• Koh DW, Dawson TM, Dawson VL. Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res. 2005;52(1):5–14. doi:10.1016/j.phrs.2005.02.011
   PubMed Web of Science ®Google Scholar
• Palazzo L, Ahel I. PARPs in genome stability and signal transduction: implications for cancer therapy. Biochem Soc Trans. 2018;46(6):1681–1695. doi:10.1042/BST20180418
   PubMedGoogle Scholar
• Pospisilik JA, Knauf C, Joza N, et al. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell. 2007;131(3):476–491. doi:10.1016/j.cell.2007.08.047
   PubMed Web of Science ®Google Scholar
• Andrabi SA, Umanah GKE, Chang C, et al. Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc Natl Acad Sci U S A. 2014;111(28):10209–10214. doi:10.1073/pnas.1405158111
   PubMed Web of Science ®Google Scholar
• Andrabi SA, Dawson TM, Dawson VL. Mitochondrial and nuclear cross talk in cell death: parthanatos. Ann N Y Acad Sci. 2008;1147(1):233–241. doi:10.1196/annals.1427.014
   PubMedGoogle Scholar
• Wang Y, Kim NS, Haince J-F, et al. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal. 2011;4(167):167. doi:10.1126/scisignal.2000902
   Web of Science ®Google Scholar
• Krukenberg KA, Kim S, Tan ES, Maliga Z, Mitchison TJ. Extracellular poly(ADP-ribose) Is a pro-inflammatory signal for macrophages. Chem Biol. 2015;22(4):446–452. doi:10.1016/j.chembiol.2015.03.007
   PubMedGoogle Scholar
• Czura CJ, Yang H, Amella CA, Tracey KJ. HMGB1 in the immunology of sepsis (not septic shock) and arthritis. Adv Immunol. 2004;84:181–200. doi:10.1016/S0065-2776(04)84005-7
   PubMed Web of Science ®Google Scholar
• Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Netw. 2018;18(4):4. doi:10.4110/in.2018.18.e27
   Web of Science ®Google Scholar
• Ditsworth D, Zong WX, Thompson CB. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem. 2007;282(24):17845–17854. doi:10.1074/jbc.M701465200
   PubMed Web of Science ®Google Scholar
• Yang Z, Li L, Chen L, et al. PARP-1 mediates LPS-induced HMGB1 release by macrophages through regulation of HMGB1 acetylation. J Immunol. 2014;193(12):6114–6123. doi:10.4049/jimmunol.1400359
   PubMed Web of Science ®Google Scholar
• Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22(20):5551–5560. doi:10.1093/emboj/cdg516
   PubMed Web of Science ®Google Scholar
• Davis K, Banerjee S, Friggeri A, Bell C, Abraham E, Zerfaoui M. Poly(ADP-ribosyl)ation of high mobility group box 1 (HMGB1) protein enhances inhibition of efferocytosis. Mol Med. 2012;18(3):359–369. doi:10.2119/molmed.2011.00203
   PubMed Web of Science ®Google Scholar
• Chandrasekaran S, Caparon MG. The streptococcus pyogenesNAD+ glycohydrolase modulates epithelial cell PARylation and HMGB1 release. Cell Microbiol. 2015;17(9):1376–1390. doi:10.1111/cmi.12442
   PubMed Web of Science ®Google Scholar
• Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair [23]. Nature. 1980;283(5747):593–596. doi:10.1038/283593a0
   PubMed Web of Science ®Google Scholar
• Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol. 2011;4:16. doi:10.1186/1756-8722-4-16
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe H, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921. doi:10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–917. doi:10.1038/nature03443
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–134. doi:10.1056/nejmoa0900212
   PubMed Web of Science ®Google Scholar
• Mądry R, Stanisławiak-Rudowicz J. Management of adverse reactions during maintenance therapy with olaparib in ovarian cancer patients. Onkol Prakt Klin Edu. 2018;4(3):167–178.
   Google Scholar
• Wiśnik E, Ryksa M, Koter-Michalak M. Inhibitory PARP1: współczesne próby zastosowania w terapii przeciwnowotworowej i perspektywy na przyszłość. Postepy Hig Med Dosw. 2016;70:280–294. doi:10.5604/17322693.1199303
   Google Scholar
• Passeri D, Camaioni E, Liscio P, et al. Concepts and molecular aspects in the polypharmacology of PARP-1 inhibitors. ChemMedChem. 2016;11(12):1219–1226. doi:10.1002/cmdc.201500391
   PubMed Web of Science ®Google Scholar
• Wahlberg E, Karlberg T, Kouznetsova E, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol. 2012;30(3):283–288. doi:10.1038/nbt.2121
   PubMed Web of Science ®Google Scholar
• Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293–301. doi:10.1038/nrc2812
   PubMed Web of Science ®Google Scholar
• Hassa PO. The molecular “Jekyll and Hyde” duality of PARP1 in cell death and cell survival. Front Biosci 2009;14:72–111. doi:10.2741/3232
   Web of Science ®Google Scholar
• Giansanti V, Donà F, Tillhon M, Scovassi AI. PARP inhibitors: new tools to protect from inflammation. Biochem Pharmacol. 2010;80(12):1869–1877. doi:10.1016/j.bcp.2010.04.022
   PubMed Web of Science ®Google Scholar
• Jain PG, Patel BD. Medicinal chemistry approaches of poly ADP-ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update. Eur J Med Chem. 2019;165:198–215. doi:10.1016/j.ejmech.2019.01.024
   PubMed Web of Science ®Google Scholar
• Thomas C, Ji Y, Lodhi N, et al. Non-NAD-like poly(ADP-ribose) polymerase-1 inhibitors effectively eliminate cancer in vivo. EBioMedicine. 2016;13:90–98. doi:10.1016/j.ebiom.2016.10.001
   PubMed Web of Science ®Google Scholar
• Kapoor K, Singla E, Sahu B, Naura AS. PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice. Mol Cell Biochem. 2014;400(1–2):153–162. doi:10.1007/s11010-014-2271-4
   PubMed Web of Science ®Google Scholar
• Ahmad A, de Camargo Vieira J, de Mello AH, et al. The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: a potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis. Pharmacol Res. 2019;145. doi:10.1016/j.phrs.2019.104263
   PubMed Web of Science ®Google Scholar
• Ghonim MA, Pyakurel K, Ibba SV, et al. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice. Clin Sci. 2015;129(11):951–962. doi:10.1042/CS20150122
   Web of Science ®Google Scholar
• Gariani K, Ryu D, Menzies KJ, et al. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. J Hepatol. 2017;66(1):132–141. doi:10.1016/j.jhep.2016.08.024
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Horváth B, Rajesh M, et al. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. J Hepatol. 2017;66(3):589–600. doi:10.1016/j.jhep.2016.10.023
   PubMed Web of Science ®Google Scholar
• Teng F, Zhu L, Su J, et al. Neuroprotective effects of poly(ADP-ribose)polymerase inhibitor olaparib in transient cerebral ischemia. Neurochem Res. 2016;41(7):1516–1526. doi:10.1007/s11064-016-1864-6
   PubMed Web of Science ®Google Scholar
• Berger NA, Besson VC, Boulares AH, et al. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol. 2018;175(2):192–222. doi:10.1111/bph.13748
   PubMed Web of Science ®Google Scholar
• Bao Z, Xiong J, Li W, Chen Z, Shen H, Ying S. Genomic instability in chronic airway inflammatory diseases. Biomed J. 2015;38(2):117–124. doi:10.4103/2319-4170.143478
   PubMed Web of Science ®Google Scholar
• Oliver FJ, Ménissier-de Murcia J, Nacci C, et al. Resistance to endotoxic shock as a consequence of defective NF-κB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J. 1999;18(16):4446–4454. doi:10.1093/emboj/18.16.4446
   PubMed Web of Science ®Google Scholar
• Soriano FG, Liaudet L, Szabó É, et al. Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. Shock. 2002;17(4):286–292. doi:10.1097/00024382-200204000-00008
   PubMed Web of Science ®Google Scholar
• Corral J, Yélamos J, Hernández-Espinosa D, et al. Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models. Am J Pathol. 2005;166(4):1089–1098. doi:10.1016/S0002-9440(10)62329-2
   PubMed Web of Science ®Google Scholar
• Nicolescu AC, Holt A, Kandasamy AD, Pacher P, Schulz R. Inhibition of matrix metalloproteinase-2 by PARP inhibitors. Biochem Biophys Res Commun. 2009;387(4):646–650. doi:10.1016/j.bbrc.2009.07.080
   PubMed Web of Science ®Google Scholar
• Lechaftois M, Dreano E, Palmier B, et al. Another “string to the bow” of PJ34, a potent poly(ADP-ribose)polymerase inhibitor: an antiplatelet effect through P2Y12 antagonism? PLoS One. 2014;9(10):e110776–e110776. doi:10.1371/journal.pone.0110776
   PubMed Web of Science ®Google Scholar
• Murakami K, Enkhbaatar P, Shimoda K, et al. Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock. 2004;21(2):126–133. doi:10.1097/01.shk.0000108397.56565.4a
   PubMed Web of Science ®Google Scholar
• Khin Hnin Si M, Mitaka C, Tulafu M, et al. Inhibition of poly (adenosine diphosphate-ribose) polymerase attenuates lung-kidney crosstalk induced by intratracheal lipopolysaccharide instillation in rats. Respir Res. 2013;14(1):126. doi:10.1186/1465-9921-14-126
   PubMedGoogle Scholar
• Lobo SM, Orrico SRP, Queiroz MM, et al. Pneumonia-induced sepsis and gut injury: effects of a poly-(ADP-ribose) polymerase inhibitor. J Surg Res. 2005;129(2):292–297. doi:10.1016/j.jss.2005.05.018
   PubMed Web of Science ®Google Scholar
• Zhang L, Yao J, Wang X, Li H, Liu T, Zhao W. Poly (ADP-ribose) synthetase inhibitor has a heart protective effect in a rat model of experimental sepsis. Int J Clin Exp Pathol. 2015;8(9):9824–9835.
   PubMed Web of Science ®Google Scholar
• Soriano FG, Nogueira AC, Caldini EG, et al. Potential role of poly(adenosine 5′-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. Crit Care Med. 2006;34(4):1073–1079. doi:10.1097/01.CCM.0000206470.47721.8D
   PubMed Web of Science ®Google Scholar
• Li L, Hu BC, Gong SJ, Yu YH, Dai HW, Yan J. Association of poly(ADP-ribose) polymerase activity in circulating mononuclear cells with myocardial dysfunction in patients with septic shock. Chin Med J (Engl). 2014;127(15):2775–2778. doi:10.3760/cma.j.issn.0366-6999.20140378
   PubMed Web of Science ®Google Scholar
• Zhang JN, Ma Y, Wei XY, et al. Remifentanil protects against lipopolysaccharide-induced inflammation through PARP-1/NF- κ B signaling pathway. Mediators Inflamm. 2019;2019. doi:10.1155/2019/3013716
   Web of Science ®Google Scholar